DOH studying Israeli saliva test for COVID-19
.
Sheila Crisostomo(The Philippine Star) – August 20, 2020 – 12: 00 am
MANILA, Philippines– Israel’s saliva test is now among the test methods for COVID-19 being studied by the Department of Health (DOH), an authorities stated the other day.
According to DOH Undersecretary Maria Rosario Vergeire, the company’s lab specialist panel has been studying the saliva test, which was reported to determine in less than a second if an individual is infected with the coronavirus or not.
” I think we got that info around three weeks or one month ago already and our Lab Professional Panel is studying the experiences of other nations that are utilizing this technique,” she kept in mind.
The experts are then anticipated to send a recommendation to DOH.
In utilizing the test package, patients wash their mouth with saline wash and spit into a vial.
The saliva will then be taken a look at using a small spectral gadget which shines light on the samples and analyze the reaction to see if it is consistent with COVID-19
The trial being done on the test sets is led by Eli Schwartz of the Center for Geographic Medicine and Tropical Illness at Sheba Medical.
Vergeire stated it is also being studied if saliva can be gathered as samples for screening to identify the presence of SARS-CoV-2.
Presently, the samples being collected in evaluating a patient using the reverse transcription-polymerase chain reaction (RT-PCR) come from “oropharyngeal.”
” We likewise use (samples from the) lower breathing tract if the patient is restricted in a healthcare facility. We get this type of sample,” she added.
The DOH is creating omnibus standards on the appropriate usage of test approaches now available in the market, such as RT-PCR, quick antibody test sets and quick antigen.
COVID medication
The Dangerous Drugs Board (DDB) has issued regulatory guidelines on the importation and sale of a conventional Chinese medications touted as COVID-19 treatment.
The DDB has issued a resolution prescribing regulative control requirements for the importation, sale, circulation and prescription of Lianhua Qingwen pills.
The capsules were earlier authorized by the Fda (FDA) as a traditional organic item as indicated in the Certificate of Item Registration.
It contains plant-based Ephedra and derivative Ephedrine, which is in your area categorized as an unsafe drug, that need to be regulated by the DDB.
The DDB kept in mind that there is low or negligible threat of abuse due to the “insignificant content” of ephedra in the medication preparation.
Just 9.14 milligrams of ephedra extract were discovered during laboratory analysis of the pill.
Still, DDB said that enforcement companies are all set to monitor the level of distribution of the product.
It cautioned the public that online sale and circulation of the capsules are forbidden and might be charged for violations versus the Philippine Pharmacy Act or Republic Act 10918.
The DDB stated that importers or distributors of the pills secure a S-5-I license or the license to import drug preparations containing controlled chemicals from the Philippine Drug Enforcement Company, with each batch accompanied by an import permit.
As for usage, Lianhua Qingwen capsules can only be recommended by a doctor with a PDEA S-2 license, even with normal prescription in triplicate copies.
The Chinese embassy invited the approval, saying that it is used to treat moderate to moderate cases of COVID-19 in China and paves the way for traditional Chinese medicine (TCM) into the regional market.— Romina Cabrera
Comments
Post a Comment